CCDC139 Activators are a diverse group of chemical compounds that have the potential to enhance the functional activity of CCDC139 through different biochemical pathways. Forskolin and IBMX, for example, are known to increase intracellular cAMP levels, which in turn activates protein kinase A (PKA). If CCDC139 is a substrate for PKA or involved in cAMP-dependent signaling, these compounds could lead to its activation. Similarly, by increasing intracellular calcium levels, Ionomycin and A23187 could activate calcium-dependent signaling pathways that may involve CCDC139. PMA, a known activator of PKC, might enhance CCDC139 activity if PKC-dependent phosphorylation is part of its regulation. Moreover, Epigallocatechin gallate (EGCG) serves as a kinase inhibitor and could lead to the activation of CCDC139 by inhibiting kinases that otherwise negatively regulate the protein or its pathways.
Additionally, LY294002 and U0126, inhibitors of PI3K and MEK respectively, could indirectly activate CCDC139 by altering the PI3K/Akt and MAPK/ERK pathways, assuming CCDC139 activity is modulated by these pathways. SB203580, a p38 MAPK inhibitor, and Anisomycin, a JNK activator, may affect CCDC139 by either shifting signaling dynamics in favor of pathways that activate CCDC139 or byactivating JNK signaling, which CCDC139 could be a part of. Sphingosine-1-phosphate (S1P) binds to G protein-coupled receptors and initiates signaling cascades that could include CCDC139 if it is indeed involved in S1P-responsive pathways. Genistein, by inhibiting tyrosine kinases, may remove competitive inhibition from other pathways, potentially leading to the activation of CCDC139 if it is under the regulatory influence of tyrosine kinase signaling. Collectively, these chemical activators, through their targeted influence on cellular signaling pathways, offer a spectrum of mechanisms that could lead to the enhanced functional activity of CCDC139 without necessarily upregulating its expression or requiring direct interaction with the protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calcium-dependent signaling pathways, which may lead to the activation of CCDC139 if it is involved in such pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in various signaling pathways. If CCDC139 is regulated by PKC-dependent phosphorylation, PMA may enhance its functional activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, which leads to increased cAMP levels. Through the same mechanism as Forskolin, IBMX could lead to the activation of CCDC139 if it is involved in cAMP/PKA-regulated pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that may lead to the activation of CCDC139 by inhibiting kinases that negatively regulate CCDC139 or its associated pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could indirectly activate CCDC139 by altering signaling pathways that regulate CCDC139 activity, assuming it is influenced by PI3K/Akt signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that may enhance CCDC139 activity by modulating the MAPK/ERK pathway, if CCDC139 is influenced by this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which may shift signaling dynamics in favor of pathways that activate CCDC139, provided it is associated with p38 MAPK signaling. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P engages with G protein-coupled receptors to activate signaling cascades that could include CCDC139 activation if it participates in these pathways. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator that can influence the JNK signaling pathway, potentially leading to the activation of CCDC139 if it is regulated by JNK signaling. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that, similar to Ionomycin, raises intracellular calcium levels and may activate CCDC139 if it is part of calcium-dependent signaling processes. | ||||||